ID

14531

Description

Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00148070

Link

https://clinicaltrials.gov/show/NCT00148070

Keywords

  1. 4/19/16 4/19/16 -
Uploaded on

April 19, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Metastatic Breast Cancer NCT00148070

Eligibility Metastatic Breast Cancer NCT00148070

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with biopsy proven, measurable metastatic breast cancer. patients with bone-only, and/or effusion-only disease are excluded.
Description

Metastatic breast cancer

Data type

boolean

Alias
UMLS CUI [1]
C0278488
UMLS CUI [2]
C0153690
UMLS CUI [3]
C0747641
karnofsky performance status equal to 70 or greater.
Description

Karnofsky performance status

Data type

boolean

Alias
UMLS CUI [1]
C0206065
anc > 1500, hgb > 10, plt > 100.
Description

ANC, hemoglobin and platelets

Data type

boolean

Alias
UMLS CUI [1]
C0948762
UMLS CUI [2]
C0019046
UMLS CUI [3]
C0032181
patients with some degree of hepatic dysfunction and renal dysfunction are encouraged, in order to evaluate the ability of the ermbt in tailoring dose in these patient populations.
Description

Liver and renal function

Data type

boolean

Alias
UMLS CUI [1]
C0232741
UMLS CUI [2]
C0232804
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
age less than 18 years.
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
allergy to erythromycin.
Description

Allergy to erythromycin

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0014806
previous treatment with docetaxel. prior paclitaxel is allowed.
Description

Docetaxel and paclitaxel

Data type

boolean

Alias
UMLS CUI [1]
C0246415
UMLS CUI [2]
C0144576
grade > 2 peripheral neuropathy.
Description

Peripheral neuropathy grade

Data type

boolean

Alias
UMLS CUI [1]
C3869673
no confounding factors present to provide misinterpretation of data (i.e., concurrent malignancy).
Description

Confounding factors

Data type

boolean

Alias
UMLS CUI [1]
C0009673
patients who are pregnant or nursing will not be eligible for this protocol. women of childbearing age who are not practicing reliable birth control must have a documented negative serum hcg.
Description

Gynaecological status

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3,1]
C3831118
UMLS CUI [3,2]
C0032976
patients who require concurrent treatment with drugs which are known to induce or inhibit cyp3a activity will be ineligible for the trial. this list includes the drugs midazolam, anti-mycotic agents (ketoconazole and related compounds), macrolide antibiotics (erythromycin and related compounds), nifedipine, anti-seizure drugs, and rifampin (induction).
Description

Cyp3a inhibitors

Data type

boolean

Alias
UMLS CUI [1]
C3850056

Similar models

Eligibility Metastatic Breast Cancer NCT00148070

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Metastatic breast cancer
Item
patients with biopsy proven, measurable metastatic breast cancer. patients with bone-only, and/or effusion-only disease are excluded.
boolean
C0278488 (UMLS CUI [1])
C0153690 (UMLS CUI [2])
C0747641 (UMLS CUI [3])
Karnofsky performance status
Item
karnofsky performance status equal to 70 or greater.
boolean
C0206065 (UMLS CUI [1])
ANC, hemoglobin and platelets
Item
anc > 1500, hgb > 10, plt > 100.
boolean
C0948762 (UMLS CUI [1])
C0019046 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
Liver and renal function
Item
patients with some degree of hepatic dysfunction and renal dysfunction are encouraged, in order to evaluate the ability of the ermbt in tailoring dose in these patient populations.
boolean
C0232741 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Age
Item
age less than 18 years.
boolean
C0001779 (UMLS CUI [1])
Allergy to erythromycin
Item
allergy to erythromycin.
boolean
C0020517 (UMLS CUI [1,1])
C0014806 (UMLS CUI [1,2])
Docetaxel and paclitaxel
Item
previous treatment with docetaxel. prior paclitaxel is allowed.
boolean
C0246415 (UMLS CUI [1])
C0144576 (UMLS CUI [2])
Peripheral neuropathy grade
Item
grade > 2 peripheral neuropathy.
boolean
C3869673 (UMLS CUI [1])
Confounding factors
Item
no confounding factors present to provide misinterpretation of data (i.e., concurrent malignancy).
boolean
C0009673 (UMLS CUI [1])
Gynaecological status
Item
patients who are pregnant or nursing will not be eligible for this protocol. women of childbearing age who are not practicing reliable birth control must have a documented negative serum hcg.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C3831118 (UMLS CUI [3,1])
C0032976 (UMLS CUI [3,2])
Cyp3a inhibitors
Item
patients who require concurrent treatment with drugs which are known to induce or inhibit cyp3a activity will be ineligible for the trial. this list includes the drugs midazolam, anti-mycotic agents (ketoconazole and related compounds), macrolide antibiotics (erythromycin and related compounds), nifedipine, anti-seizure drugs, and rifampin (induction).
boolean
C3850056 (UMLS CUI [1])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial